The co-existence of mental illness and psychoactive drug or other substance use problems — otherwise known as ‘comorbidity’ or ‘dual diagnosis’ — is an issue which has been on the radar of the EU drugs agency (EMCDDA) for over a decade (1).
Representatives of candidate, potential candidate and neighbouring countries of the EU are joining members of the EMCDDA’s Reitox network in Lisbon today for the kick-off of the agency’s fourth Reitox week.
An EMCDDA Paper released today provides an overview of the information available on drug-related homicide (DRH) in Europe. This first snapshot provides practitioners and policymakers with the current state of the art on this topic.
What are the most (cost-) effective ways to prevent and control communicable diseases in prison settings? In their joint public health Guidance, ECDC and the EMCDDA present evidence on active case finding as a key measure to diagnose communicable diseases early. The publication is launched in the first Spring European Hepatitis-HIV Testing Week (18–25 May 2018).